Neuroblastoma Drug Development: Potential Surrogate Endpoint Gets US FDA Panel Backing

 
• By Brenda Sandburg

Advisory committee supports further research on end-of-induction response as an early interim clinical endpoint for drugs in treatment of high-risk neuroblastoma. FDA has approved two drugs for this rare disease in children, who have a 40-50% chance of long-term survival.

Neuroblastoma
FDA advisory committee favors further research on potential surrogate endpoint for high-risk neuroblastoma • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers